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I. LIST OF ABBREVIATIONS 2 
Symbols and abbreviations are in accordance with the recommendations of the IUPAC-IUB 
Commission on Biochemical nomenclature: Nomenclature and symbolism for Amino Acids 
and Peptides (J Biol Chem 1984: 219 :345-373) 
Ate aminotetraline-2-carboxylic acid 
BSA Bovine serum albumin 
Car 1,2,3,4-tetrahydro-p-carboline-1 -carboxylic acid 
Cpa parachloride-phenylalanine 
Cys cysteine 
Dbr 3,5-dibromide-phenylalanine 
Dmf 2,4-dimethylphenylalanine 
GPCR G protein-coupled receptor 
Igl indanylglycine 
Kj Inhibition constans 
Mca P-mercapto-P,P-cyclopentamethylenepropionic acid 
MeOAtc 6-methoxy-2-aminotetraline-2-carboxylic acid 
MeTcc l,2,3,4-tetrahydro-l-methyl-P-carboline-3-carboxylic acid 
Mpa mercaptopropionic acid 
OT oxytocin 
OTR oxytocin receptor 
Pen P,'-dimethylcysteine 
Pff pentafluorophenylalanine 
Phe phenylalanine 
PMSF phenylmethyl-sulfonyl fluoride 
Tcc 1,2,3,4-tetrahydro-P-carboline-3-carboxylic acid 
Tic 1,2,3,4-tetrahydroisoquinoline-l-carboxylic acid (Tic) 
Tmf 2,4,6,-trimethyphenylalanine 
Trp tryptophan 
Tyr tyrosine 
VP vasopressin 
VPR vasopressin receptor 
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II. INTRODUCTION 
According to the recommendation of the WHO preterm birth is defined as a gestational age 
less than 37 completed weeks of pregnancy or less than 259 days from the first day of the last 
menstrual period. Effective methods for treatment of preterm labor have become major goals 
in modern obstetrics because preterm birth is the leading cause of infant morbidity and 
mortality. The average duration of gestation in women is 40 weeks, it is estimated that there 
are nearly 13 million preterm babies born worldwide each year, with an incidence of between 
5,8 % (Oceania) and 10,6 % (North America) of all birth. In Europe, the overall incidence of 
preterm birth is approximately 5,9 %, or an expected annual population of 375,000. Of these 
pregnancies approximately 100,000 each year are "potentially preventable". [Villar, J., 1994] 
Premature infants are more at a risk for development of such problems as respiratory distress 
syndrome, hyaline membrane disease, necrotizing enterocolitis and sepsis [McCombs, J., 
1995]. Morbidity resulting from prematurity often causes lifelong disabilities and therefore 
impacts on the family, society, and healthcare economics. Despite the routine use of tocolytic 
agents in the recent decade, the incidence of premature delivery has not declined. Therefore a 
major priority in obstetric research is the prevention of prematurity. 
Probably the most important risk factor known is a previous preterm birth, which is associated 
with about a three-fold increase in the risk of a further preterm delivery [Mercer, M.C., 1996]. 
Other risk factors, such as minority ethnic origin, low socio-economic class, work during 
pregnancy and smoking have a significant association with preterm labor. Maternal 
physiological problems that may predispose a patient to preterm labor include serious renal or 
cardiovascular disease, severe anaemia, severe hyperthyroidism, infection or poorly 
controlled diabetes [Caritis, S.N., 1988]. 
Term and preterm labor are considered to have fundamentally similar processes. They share a 
common terminal pathway consisting of uterine contractility, cervical dilation, and activation 
of the amniotic membranes [Romero, R., 1994]. This involves anatomical, biochemical, 
endocrinological and clinical events that occur in the fetus and in the mother. The principal 
difference between term and preterm labor is how they are activated. It has been proposed that 
term labor results from the physiological activation of the common terminal pathway, whereas 
preterm labor is a pathological condition caused by multiple aetiologies which activate one or 
more of the components of this pathway [Romero, R., 1994]. 
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III. TREATMENT OF PRETERM LABOR 
III/l. P2-adrenergic receptor agonists 
Several pharmacological approaches focus on the inhibition of preterm uterine contractility. 
The major form of currently applied treatment is the administration of selective P 2 - a d r e n e r g i c 
agonists that inhibit myometrial contractility by activating of the receptor-mediated 
adenylcyclase cascade. The first P-adrenergic agonist to be administrated clinically to treat 
preterm labor was isoxuprin [Higby, K., 1993]. Although it was somewhat successful, it 
produced significant cardiovascular adverse effects. To decrease the adverse effects, ritodrin 
was licensed specially for obstetric use. Nowadays, worldwide used selective P 2 - a g o n i s t s in 
obstetrics include fenoterol, terbutalin and hexoprenalin. Presently only hexaprenalin is used 
in Hungary. 
The P 2 - a g o n i s t s are initially administered by intravenous infusion. Following parenteral 
administration, the patient receives oral medication until delivery. If the labor recurs, the 
parenteral medication can be reinstated [McCombs, J., 1995]. Although this therapy can 
prolong pregnancy for 48 hours, it does not reduce the incidence of preterm birth or perinatal 
morbidity or mortality. Moreover, long-term (1 week) administration of these drugs tends to 
cause down-regulation and desensitisation of the p 2 - r e c e p t o r s , possibly affecting the ability of 
the medication to inhibit uterine contraction. Besides desensitisation adverse effects are of the 
major consideration in the use of the P 2 - a g o n i s t s , as well. They are associated with significant 
maternal and foetal side-effects. The risks of the tocolysis with P 2 - a g o n i s t s include fluid 
overload (possible stimulation of the renin-aldosterone system, increase in antidiuretic 
hormone), and pulmonary oedema. The precise mechanism by which pulmonary oedema 
develops in pregnant women treated with P-agonists is unknown and most likely 
multifactorial, fluid retention is one possible contributory factor [Pisani R.J., 1989; Clesham 
G.J., 1994]. Other complications include increased heart rate (as much as 30-40% increase), 
myocardial ischaemia (isolated systolic hypertension, increased myocardial oxygen 
consumption, decreased coronary blood flow, hypoxia, and hypokalemia. Agitation, tremor 
and nervousness also are frequently reported in patient receiving these medications [Caritis, 
S.N., 1988]. These drugs also have diabetogenic effect, they increase blood glucose with a 
resultant increase of insulin secretion [McCombs, J., 1995] 
This broad side effect spectrum leads to contraindication in a part of the patients. 
III./2 Magnesium sulphate 
Side effect and clinical conditions that contraindicate the use of [3-sympatomimetics have 
served to focus of attention on the use of Magnesium sulphate given intravenously as an 
alternative tocolytic drug. In 1959 Hall et al. demonstrated that strips of human gravid uterine 
muscle showed reduced contractility in the presence of magnesium ion [Hall D.G., 1959]. 
Magnesium sulphate is able to inhibit the contraction of the uterus and to influence 
appropriately the eclampsia. It can delay the delivery for at least 48 h and generally occurred 
in more than 90% of the patient. Magnesium therapy is usually initiated with intravenous 
bolus of magnesium followed by an infusion of 2-4 g/h until contractions ceased [Wilkins IA., 
1988]. Although similar efficacy is reported for magnesium sulphate and P-agonists, their 
adverse effect profile differs. The adverse effects reported most often with magnesium 
sulphate are lethargy, flushing and nausea. Serious consequences, like respiratory depression 
and cardiac arrest, as well as foetal bradycardia and loss of heart rate variability do not usually 
occur until the serum magnesium concentration exceeds 5-8 mg/dL [Wilkins IA., 1988]. One 
disadvantage with magnesium sulphate is the lack of an effective oral dosage form for 
maintenance use following parenteral therapy. 
III./3. Prostaglandin Synthetase Inhibitors 
It is generally believed that prostaglandins are of major importance in the regulation of 
contractility of both the nonpregnant and pregnant uterus. The prostaglandins produced by the 
decidua and myometrium have similar effect to OT, however reducing the PG- synthesis with 
nonsteroidal anti-inflammatory agents (NSAID) as COX inhibitors is an obvious possibility 
for tocolysis. Prostaglandin F2a is able to stimulate uterine contractility during each phases of 
the menstrual cycle as well as all stages of pregnancy, in contrast to OT that acts only in late 
pregnancy. Among the NSAID indometacin has been studied most extensively for the 
treatment of preterm labor [Morales WJ., 1993]. (The salicylate derivates can not be 
administered with this indication, because of their irreversible binding to COX.). The risks of 
indomethacin administration are both maternal (peptic ulceration, gastrointestinal bleeding) 
and foetal. The foetal complications involve oligohydramnion [Hendricks SK., 1990] and 
intrauterine constriction of the ductus arteriosus, which may result in pulmonary hypertension 
[Macones, G.A., 1997; Moise KJ., 1988; Norton ME., 1993]. 
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III./4 Calcium channel blockers 
Another possibility of the relaxation of the uterus is the administration of the Ca2+-channel 
blockers. Nifedipine and other dihydropiridines have direct effect on uterine smooth muscle, 
they decrease the Ca2+-influx, intracellular Ca2+ level, thus the motoractivity of the uterus. 
Therefore, the Ca2+-channel blockers are also used for tocolysis, but an obvious side effect is 
that they can cause significant hypotension. Mainly nifedipine is used for supplementary 
medication of preterm contractions. Their maternal side effect profile is better than P-agonists 
but effects on the foetus have caused concern [hnpey, L., 1993]. Of particular concern is the 
interaction of the Ca2+-channel blockers with magnesium sulphate, being reported as causing 
respiratory failure [Ben-Ami, M., 1994]. 
Premature labor continues to be a therapeutic dilemma for obstetricians and pharmacists. The 
above mentioned drugs available for the treatment of preterm labor are not consistently 
effective. All have serious potential effects on the mother, the foetus, or both. Therefore, the 
greatest challenge in the management of preterm labor is the lack of a specific pharmacologic 
agent for treatment. Perhaps when the cause of premature labor is identified, a more specific 
and less harmful agent can be developed. 
IV. ROLE OF OXYTOCIN ANTAGONISTS 
IV/1. Physiology and pharmacology of OT 
Although the causes of preterm labor are multifactorial, it is becoming more apparent that 
oxytocin (OT) has an important role in the preterm birth. It is well accepted that both OT 
itself and the sensitivity of the uterus to OT play crucial role in the initiation of both normal 
and pathologically early deliveries [Fuchs AR., 1982; Takahashi K.,1980]. 
In 1906 Sir Henry H. Dale demonstrated that the posterior pituitary gland contains a 
substance that has uterine stimulating properties [Higuchi T., 1995]. The application of such 
an extract to induce labor was reported as early as 1911. Further investigations cleared up that 
posterior pituitary extracts contain two main biologically active peptides, which were named 
after their physiological effects: oxytocin delivered from a Greek world meaning "swift-birth" 
and vasopressin (VP) ("vasoconstrictor"). Since the posterior pituitary is part of the central 
nervous system and it releases these substances to the blood via median eminence and so they 
can reach the site of the action in the body they become classified as neuronhormones 
[Szentágotai JRM., 1994]. 
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In the 1950s Du Vigneaud and co-workers established the structure of OT. Du Vigneaud 
awarded Nobel Prize in 1955 for the first successful synthesis of a biological active peptide in 
the test tube. OT is a nine-amino acid peptide consisting of a six-member ring formed by 
disulfide bounds between position 1 and 6 and three amino acids tail (Figure 1). It is 
structurally similar to vasopressin (VP), differing by only 2 amino acids and thought to evolve 
from a common ancestral gene. 
Oxytocin 
Figure 1. 
Chemical structure of the OT molecule 
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The aminosequency of the OT is: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2. Recent 
findings demonstrate that this hormon acts in human as a neurohormone (it stimulates smooth 
muscle contraction in the pregnant uterus during delivery and enhance milk ejection), as a 
neuroregulator (it plays role in the maternal behaviour, stress, anorexia, in the modulating 
cerebrovascular responses to hypoxia) and as a paracrine substance in the decidua which may 
trigger the onset of the parturition. 
Genes for both OT and VP reside on chromosome 20 in opposite transcriptional orientation 
separated by intergenic sequences. OT is initially synthesized as a 125-amino acid 
preprohormone in the magnocellular neurons of the supraoptic and paraventricular nuclei of 
the hypothalamus. The prohormone is first cleaved by a serine endoprotease to form oxytocin-
Gly-Lys-Arg. This is further cleaved by convertases and carboxypeptidase E in the secretory 
granules to oxytocin-Gly which is -amidated to OT by peptidylglycine. The rate-limiting step 
is the conversion of oxytocin-Gly to OT. The cleavage of the precursor to OT occurs in the 
secretory vesicule during axonal transport to the neurohypophysis. 
OT is rapidly metabilized in the liver, kidney and the placenta. In additional, the plasma from 
pregnant women metabolises OT to biologically inactive peptides due to the action of an 
enzyme produced by the placenta and released into the blood, cystine aminopeptidase 
(oxytocinase). These enzyme cleaves the Cys^Tyr2 bond and then cleaves Tyr. Other 
enzymes known to metabolize OT are postproline endopeptidase, which cleaves the Pro7-Leu8 
bond [Knobil E., 1998]. 
OT is known to act through specific OT receptor (OTR). Kimura et al. first isolated and 
identificated the human OTR using an expression cloning strategy [Kimura T., 1992], (Figure 
2). 
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Figure 2. 
The 7 transmembrane domain of the OTR 
The encoded receptor is a 389 amino acid polypeptide with 7 transmembrane domains and 
belongs to the class I G protein-coupled receptor (GPCR) family. The OTR is a typical 
member of the rhodopsin-type (class I) GPCR family. The seven transmembrane a-helices are 
the most highly conserved among the GPCR family members. Conserved residues among the 
GPCRs may be involved in a common mechanism for activation and signal transduction to 
the G protein. The major second messenger system that mediates uterine contraction is the 
phospholipase C, inositol triphosphate pathway. OTR binding results in activation of G-
proteins, in particular the Gq and Gj families. 
On the basis of studies with model GPCRs it is assumed that the switching from the inactive 
to the active conformation is associated with a change in the relative orientation of the 
transmembrane domain 3 and 6, which then unmasks binding sites [Gimpl, G., 2001], In the 
case of the OT binding characterisitic, the NH2 terminus of the OTR takes part in hormone 
binding and probably interacts with the hydrophobic leucyl residue in position 8 of the 
ligands. The NH2 terminal domain and the first extracellular loop of the OTR are proposed to 
interact with the linear COOH-terminal tripeptidic part of the OT, whereas the second 
intracellular loop of the OTR could be identified to interact with the cyclic hormone part 
(Figure 3) [Postina R., 1996]. Several studies indicate that the binding sites of the OT 
antagonists are different from the agonist binding site. The binding site for the peptide OT 
antagonists [Elands J., 1988] was formed by the transmembrane helices 1,2 and 7 with a 
9 
major contribution to binding affinity by the upper part of helix 7. These regions did not 
participate in OT binding [Postina R., 1996]. 
m f j c r.iR 
Figure 3. 
The structure and the amino acids sequence of the OTR 
OT is the most potent known parturient. The action OT is mediated by binding to specific 
OTR present in the uterus and other target tissues. Around the onset of labor, uterine 
sensitivity to OT markedly increases. This is due to both the upregulation of OT receptor 
mRNA levels and strong increase in the density of myometrial OT receptors, reaching a peak 
during early labor. This has been demonstrated both in rats and in human species, in which 
receptor levels rise during early labor to 200 times that in nonpregnant state [Fuchs AR., 
1984], Thus, at the onset of the labor OT can stimulate uterine contractions at levels that were 
ineffective in the nonpregnant state. OTR is also found in the decidua, where OT can 
stimulate the production of PGF2a. At the end of pregnancy, an increased secretion of PGF2a 
leads to luteolysis and causes progesteron withdrawal and initiation of labor. After parturition, 
the concentration of OTR rapidly decline. In rats, the uterine OTR mRNA level decreased 
10 
more than sevenfold within 24 h [Zingg H., 1995]. Possibly, the down-regulation of the OTRs 
is necessary to avoid unwanted contractile responses during lactation when OT level is raised. 
Clinically, the primary drug used to induce labor in women is synthetic OT. OT is infused iv. 
beginning at about 2 mU/min and the dose is increased every 20-30 min until effective uterine 
contractions are archived (the maximal OT dose is 12 mU/min). The uterus is more sensitive 
to OT during the last trimester of pregnancy due to the increase in the number of myometrial 
OTR (Knobil E.,1998) 
The widespread use of synthetic OT in clinical obstetric practice speaks to its effectiveness in 
initiating parturition, and aroused a question whether OT antagonists are able to prevent 
preterm labor. (Goodwin et al., 1994). According to the all of the above mentioned it is well 
accepted that the OT system may be regarded as a key regulator of parturition, with the 
induction of OTR as a trigger event. Therefore, the blockade of the uterine OTR is one of the 
logical approaches to prevent preterm labor. 
IV/2. OT antagonists 
The parturition process can be divided into two phases: the endocrine and the paracrine phase. 
The endocrine phase begins with an increase in the oestrogen/progesterone ratio that brings 
about the release of OT and nocturnal uterine contractions. They contribute to the pushing of 
the fetal head into the ripening and opening the cervival os. As the cervix opens, this exposes 
the chorioamnion membranes to vagina bacteria and this, along with the trauma of the head 
pushing into the cervix, induces an inflammatory-like reaction that brings blood elements into 
the lower uterine segment and cervix. Cytocines are released locally and stimulate PG 
production and the control of the uterine contractions switches from those dominated by OT 
to paracrine and autocrine factors such as PGs. Thus, depending on the phase of the delivery 
process, different tocolytics may be needed to stop labor. Based on this concept, antagonists 
to OT will be the most effective in the endocrine phase, whereas inhibitors to PG production 
or inflammatory reactions will be more effective during the paracrine phase of parturition. 
Thus, the current research focus is on selecting factors in the early stages of the parturition 
process that indentify patients at risk and treating with agents such as OT antagonists that will 
stop uterine activity in the endocrine phase. 
This is the reason that, there has recently been an increasing tendency toward the rational 
design of highly active and selective analogues of different peptides. In the past few decades, 
hundreds of OT analogues has been synthesised in an attempt to obtain selective and active 
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analogues, and to know more information about the structure-activity relationship. Although 
the first OT analogues with antagonistic properties were described by Law and du Vigneaud 
in 1960, but only one of the synthesised analogues, atosiban (l-deamino-D-Tyr(OEt)2-
Thr4Orn8-OT) have been licensed in human medical practice for the treatment of preterm 
labor [Melin P., 1994] 
The specificity for OT receptors is the key to the clinical application of any OT antagonist, 
since the major problem with all current tocolytic agents is their systemic activity, which 
causes potentially harmful multi-organ side-effects. The efficacy and safety of the atosiban 
was investigated in a randomised, double-blind, placebo-controlled trial with tocolytic rescue 
(Romero, R., 2000). In this study the treatment of patients in preterm labor with atosiban 
resulted in prolongation of pregnancy for up 7 days for those at a gestational age >28 weeks 
with a low rate of maternal-fetal adverse effects. In addition, at a gestational age >28 weeks, 
infant morbidity and mortality of atosiban-initiated standard care were similar to those with 
placebo-initiated standard care. The side effect profiles of atosiban and placebo were 
comparable, with exception of a higher incidence of injection-site reactions during the 
maintenance among patients receiving atosiban. The safety results associated with atosiban 
treatment compare favourably with published data on the P-sympathomimetics, including 
ritodrine, the only tocolytic agent approved in the United States. The superiority of atosiban 
maternal-fetal safety compared with that of P-agonists has also been demonstrated in 2 
randomized clinical trials. Although the delay in delivery was comparable between the 
atosiban and P-agonist group, maternal/fetal outcomes were substantially better with atosiban. 
Adverse events were reported more frequently in women administered P-agonists, particularly 
maternal cardiovascular adverse events. 
During the development of the OT antagonists, modification of the OT molecule at positions 
1, 2, 7 and 8 produced analogues with higher receptor affinity and selectivity for the 
myometrium in vitro (Figure 4). 
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Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly 
OT 
Deamino-Cys-Xxx-Ile-Gln-Asn-Cys-Sar-Orn-Gly 
Synthesised peptides 
Figure 4. 
Generál structure of the synthesised OT analogues 
Most of the OT antagonists describe to contain Mpa, Mca, Pen instead of Cys at position 1. 
Lacking of the N-terminal amino group of the cystein in the first position protects the peptide 
molecule against the eliminating oxytocinase enzyme [Gronzka, Z., 1991]. It is also known 
that the substitution of the Pro with Sar at position 7 results in highly potent OT agonist with 
weak antidiuretic activity [Gronzka, Z., 1983; Pávó I., 1994]. This considerable selectivity is a 
characteristic feature of OT analogues with antagonist potency. Another possibility for the 
modification is the Leu at position 8. The amino acid at position 8 also has a role in the 
binding of the antagonists to the OT receptor. The most potent OT antagonists contain basic 
amino acid (Arg/Orn) instead of apolar Leu at position 8 [Lebl, M., 1987]. The results of 
Hurby et al. and Manning et al. pointed the importance of the amino acids at position 2 for 
antagonist activity together with the presence of the basic amino acids in position 8 [Hruby 
VJ., 1990; .Manning M., 1995] 
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V. AIM OF THE STUDY 
The data summarized previously illustrate that the tocolytic therapy is not a solved problem, 
while it is one of the most important problems of the healthcare. In spite of the fact, that 
theoretically the spontaneous activity of the uterus can be influenced in many ways, still, in 
practice the effective agents in use do not correspond to the expectations of the ideal 
medicines. The current classes of tocolytic agents are far from the ideal because all available 
agents have documented serious adverse effects for either the mother or the infant, or both. 
The aim of our study was the in vitro, in vivo pharmacological characterization of more 
effective and selective OT antagonists in cooperation the Department of Pharmacodynamics 
and Biopharmacy, Department of the Medical Chemistry and the Department of the 
Pharmaceutical Chemistry of the University of Szeged. We set out to establish the optimal 
size of the apolar side-chain at position 2 and in parallel to find the optimal conformational 
constraints. Our approaches in the design of more effective OT antagonists are based mainly 
on the incorporation of bulky apolar side-chain amino acids with a conformationally 
constrained restricted feature at position 2. 
These synthesized peptides are l-deamino-7-sarcosine-8-arginine analogues. The appropriate 
modification of the Tyr at position 2 plays a crucial role in determining the antagonistic 
property. 
This study reports the in vitro and in vivo pharmacological investigations of the 
new synthesized OT antagonists with general structure [Mpa1Xxx2Sar7Arg8]-OT, 
substituted at position 2 with conformationally constrained and bulky amino acids, and 
the concluded structure-effect relationships as guidelines for the further design of OT 
antagonists. 
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According to the amino acid at position 2, the newly synthesised OT analogous can be 
divided into two groups: 
A) differently substituted Phe analogues with conformational constrains: D- and L-
pentafluorophenylalanine (Pff), parachloride-phenylalanine (Cpa), 3,5-dibromide-
phenylalanine (Dbr), 2,4-dimethylphenylalanine (Dmf), 2,4,6,-trimethyphenylalanine 
(Tmf 
A. 
C O O H 
C H — N H „ 
I 
C H , 
C H , 
C H , 
Dmf 
C O O H 
Pff 
C O O H 
Dbr 
C H - N H , C H — N H , 
C H , 
CI 
Tmf Cpa 
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B) rigid structure - containing Phe, Trp and O-methyl Tyr analogous: indanylglycine [D-, 
and L-Igl], aminotetraline-2-carboxylic acid (Ate), 6-methoxy-2-aminotetraline-2-carboxylic 
acid [MeOAtc], conformationally constrained derivatives of tryptophan: 1,2,3,4-tetrahydro-l-
methyl-p-carboline-3-carboxylic acid (L- and D-MeTcc), 1,2,3,4-tetrahydro—p-carboline-3-
carboxylic acid (L- and D-Tcc), 1,2,3,4,-tetrahydro-P-carboline-l-carboxylic acid (Car-I, and 
II), 1,2,3,4-tetrahydroisoquinoline-l-carboxylic acid (Tic) and tryptophan (Trp) 
B. 
C H 3 0 
Igl Ate MeOAtc 
C O O H 
r X - C H , 
" N 
I 
H 
N H , 
- C O O H 
Tic Trp 
r ^ N 
N H 
C O O H 
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VI. MATERIALS AND METHODS 
VI/1. Mating of animals 
Animal investigations were carried out with the approval of the Ethical Committee for Animal 
Research, University of Szeged (registration number 23/1999), in accordance with the 
Guiding Principles for the Care and Use of Research Animals. Sexually mature female 
Sprague-Dawley rats (body mass: 200-300 g) and Charles River guinea-pigs were used in the 
experiments. Mating with males was carried out in the early morning hours. Copulation was 
justified by the presence of a copulation plug or spermatozoa in the vagina. The day of 
conception was considered to be the first day of pregnancy. Animals were housed in 
temperature and humidity-controlled, light-regulated (12 h of light, 12 h of dark) rooms, with 
water and food intake ad libitum. 
VI/2. Membrane preparation 
The affinities and the selectivities of the synthesized peptides for the OTR and VP receptor 
(VPR) were determined by radioligand binding assay. 
The OTR binding assays were carried out on a uterine plasma membrane fraction of term 
pregnant guinea-pig uterus. The plasma membrane was prepared by a modification of the 
method described by Fuchs et al.[Fuchs AR., 1992]. Uterine tissue was minced and 
homogenized in 10 vol ice-cold buffer containing 10 mM Tris-HCl, 1.5 mM EDTA, 0.5 mM 
dithiotreitol and 1 mM PMSF; pH 7.5. After homogenization with an Ultra Turrax 
homogenizer, the suspension was centrifiiged at 1000 x g for 10 min at 4 °C. The resultant 
supernatant was centrifuged at 100 000 x g for 60 min at 4 °C. The pellets were washed and 
resuspended for storage in Ca2+-free Hanks' salt solution with 1 mM PMSF at a protein 
concentration of approximately 10 mg/ml at -70 °C. 
Rat kidney inner medulla containing VP2 receptors and the rat liver plasma containing VPi 
receptors were prepared by the following method [Marchingo AJ., 1988]. Adult male 
Sprague-Dawley rats (200-300 g) were killed by stunning and decapitation. The 
medullopapillary region of the kidneys and the livers were homogenized with an Ultra Turrax 
in 20 vol ice-cold buffer containing 10 mM Tris-HCl and 0.1 mM PMSF; pH 7.4. The 
homogenate was centrifuged at 500 x g for 5 min to remove all debris and nuclei. The 
supernatant was centrifuged at 20 000 x g for 20 min, and the pellet was resuspended in ice-
cold incubation buffer, containing 100 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 0.5 mg/ml 
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bacitracin, and 100 IU/ml aprotinin and recentrifiiged at 20 000 x g. The final pellet was 
resuspended for storage in 10 vol incubation buffer. 
VI/3. Receptor assay 
The affinities of OT and its analogues for the OTR and VPRs were determined by homologue 
and heterologue displacement analyses. In the OTR assay, the assay buffer consisted of 25 
mM Tris-HCl, 1 mM MnCl2, 1 mM PMSF and 0.1% BSA; pH 7.5. The affinity of the OT 
analogue was investigated in the presence of 1 nM [3H]oxytocin (44 Ci/mmol) at 22 °C for 
60 min. In the case of VPR assay, the assay buffer contained 100 mM Tris-HCl, 10 mM 
MgCL, 0.5 mg/ml bacitracin, 100 IU/ml aprotinin and 0.1% BSA. The competition binding 
assays were carried out in the presence of 1 nM [3H]vasopressin (75 Ci/mmol) at 25 °C for 
120 min. In both cases, the non-specific binding was determined in the presence of 10"5 M 
unlabelled OT and VP. The bound ligand was separated from the free ligand by rapid 
filtration through a Whatman GF/C glass fibre filter, using a Brandel M24R cell harvester. 
Specific binding was determined by subtracting the non-specific binding from the total binding. 
VI/4. Measurement of uterine contraction in vitro 
Uteri were removed from 60-65-day pregnant guinea-pig, and trimmed of fat, the foeto-
placental units were removed and the decidua was scraped off. A uterine muscle strip (10 mm 
long and 10 mm wide) was suspended vertically in a 10 ml organ bath containing Van Dyke-
Hastings solution. Van-Dyke Hasting solution was used in these experiments, the composition 
of which was a follows (in milligrams per liter): sodium chloride 113, potassium chloride 6.2, 
calcium chloride 0.44, magnesium chloride 0.47, sodium bicarbonate 29.8, sodium-
dihydrogen-phosphate 0.83, disodium-hydrogen-phosphate 0.26, and glucose 5. The solution 
was equilibrated with a mixture of 95 % oxygen and 5 % carbon dioxide at pH 7.4 and the 
standard bath temperature was 37 °C. The initial tension was set to about 1.5 g, which was 
relaxed to about 0.5 g at the end of the equilibration. 
Before the onset of the experiments uterine strips were equilibrated for 60 min and allowed to 
contract spontaneously and display stable rhythmic contractions. Repeating washing of the 
tissue was use during this period. At the end of the adaptation period, the antagonists (10 "8 
M) were added to the tissue bath in a volume of 50 fil. After a 30-min incubation in the 
presence of the antagonist increasing doses ranging from 10"9 to 10"3 M OT were administered 
in cumulative manner in a volume of 50 fil. The spontaneous contractility of the uterine strip 
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was registered as control for 180 s. The OT responses were measured as the area under the 
curve during a 3 minute period after administration of each dose of OT. The contractions were 
measured with a strain gauge transducer (SG-02, Experimetria U.K. Ltd.) and recorded by an 
ISOSYS Data Acquisition System (Experimetria U.K. Ltd.). 
W5. Measurement of uterine contraction in vivo 
In in vivo experimental pharmacological animal method the experiments were carried out on 
24 hours postpartum rat uterus. During in vivo preliminary experiments the spontaneous 
contraction were the strongest after 24 hours, though the values after 12 and 48 hours were 
also significantly increased as compared to the 1-hour value [Zupko, I., 1998] (Figure 5). 
24 hours after spontaneous delivery, female Sprague-Dawley rats were anaesthetized with 
urethane (1 g/kg, intraperitoneally). After cannulation of the jugular vein, a Millar catheter 
(Millar Instruments Inc., Houston, Texas, USA) fitted with a liquid-filled latex microballoon 
was inserted into the uterine horn through a small section above the cervical part (Figure 6). 
At the end of the 30-min equilibration period, the intrauterine pressure was recorded and the 
effects of the intravenously administered compounds were assessed by expressing the 
integrated tension relating to a 5-min period after the administration of each dose as a 
percentage of the average for three 5-min periods before the first administration. The 
maximum inhibition and the ED50 values were calculated. 
VI/6. Statistical analyses 
In the cases of the receptor binding experiments all assays were carried out at least three times in 
duplicate and values are given as means + S.EM. Binding parameters were calculated by 
nonlinear regression, Graph Pad Prism 2.01 Computer Program, Graph Pad Software, USA. 
In the in vitro and in vivo contractility studies the contractile response was measured as the 
area under the curve during a 3-min or 5-min period. Areas under curves were evaluated with 
the computer program as mentioned above. In the case of the in vitro studies for statistical 
evaluations, data were analysed by means of the ANOVA, followed by Neuman-Keuls post-
hoc test. 
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Figure 6. 
Millar chateter fitted with latex microballoon inserted into the postpartum rat uterus 
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VII. RESULTS 
VII/1. Results of receptor binding assay 
During a modern drug development the determination of the affinity and selectivity of the 
newly synthesised OT analogues to the OT and VP receptors is the first step. These 
parameters were measured by radioligand binding assay on pregnant guinea pig uterus, rat 
liver and kidney membrane. Figure 7. shows the representative displacement curves of tested 
analogues on pregnant guinea-pig uterus membrane in the presence of [3H]OT. Each drug 
displaced the [3H]OT binding in a concentration-dependent manner. 
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Figure 7. 
Representative displacement curves of OT analogues on pregnant guinea-pig uterus in the presence of Inm 
fHJOT. All assays were carried out at least three times in duplicate. 
22 
Data were analysed by an iterative nonlinear regression program. In each case the program 
determined the inhibition constants (Kj) of the tested peptides to the OT and VP receptors. 
This constant can describe the affinity of the molecule to the receptor. The inhibition constant 
is a corrigated IC50 value. The IC50 value was defined as the concentration of the antagonists 
required obtaining 50% inhibition of the specific binding. The Kj is a better parameter 
compare to the IC50 because it is independent from the concentration of the radioligand. 
Therefore the inhibition constant is used to compare the affinity of the different compounds. 
Calculation of the Kj was performed according to the Cheng and Prusoff equation. 
IC50 
Kj = 
1 +[L]/Kd 
where L is the concentration of the labelled ligand and K<j the apparent dissociation constant 
of the radioligand for the receptor. 
The lower Kj value of a compound is the higher affinity of the compound to the receptor. The 
inhibition constant values of the tested OT antagonists relative to the OT, VP] and VP2 
receptors are listed in Table 1. For comparison, atosiban was tested in the same system. 
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Table 1 
Kj values of the tested peptides for the OT, VP) and VP2 receptors 
Tested peptides 
OTR 
Kj values (nM±S.E.M.) 
VPjR VP2R 
Oxytocin 2,51 ± 0 , 6 
AVP 1.5 ± 0 . 5 0.65 ± 0.04 
Atosiban 5 , 7 6 + 1 , 4 8 1412 ± 145 667 ± 1 6 3 
1. Mpa'l-Dmf2 Sar7AVT 1,49 ±0 ,31 48,4 ± 25,7 70,8 ± 15,8 
2. Mpa'l-Tmf2 Sar7AVT 46,5 ± 19,6 2 5 4 ± 1 2 8 384 ± 99,3 
I. 3. Mpa'D-Cpa2 Sar7AVTa 9 ± 2 8 ± 2 . 5 2.8 ±0.7 
4. Mpa'D-Pff2 Sar7AVT 52,9 ± 20,5 5420 ± 2490 2250 ± 8 2 0 
5. Mpa'L-Pff2 Sar7AVT 230 ± 83,9 3420 ± 620 9950 ± 2470 
6. Mpa'L-Dbr2 Sar7AVTa 3300 2700 152 ± 4 0 
7. Mpa'L-Igl2 Sar7AVT 7,32 ± 0,37 215,4 ± 0 , 5 7 173,9 ± 0,25 
8. Mpa'D-Igl2 Sar7AVT 3,81 ± 0 , 1 8 263 ± 36,9 425 ± 29,1 
9. Mpa'S-Atc2 Sar7AVTa 369.5 ± 87 1 7 6 0 0 ± 1 8 3 8 2290 ± 4 1 0 
10. Mpa'R-Ate2Sar7AVTa 1917 ±1682 5 6 4 0 ± 1 6 3 5340 ± 6 4 0 
11. Mpa'MeOAtc2 Sar7AVT 56,2 ± 9,56 1 9 4 0 ± 1 2 3 0 1 6 4 0 ± 1 1 0 0 
12. Mpa'l-Car2 Sar7AVTa,b 8545 ± 3 3 3 0 > 104 63,5 ± 4 . 1 
II. 13. Mpa'll-Car2 Sar7AVTa'b 5 7 4 5 0 ± 1 0 6 1 > 104 17,8 ± 4 . 1 
14. Mpa'S-Tee2 Sar7AVT 1227±157 1300±26 1450±113 
15. Mpa'R-Tee2 Sar7AVT 692,8±157 1715±569 6190±269 
16. Mpa'S,S-MeTec2 Sar7AVT 2020 ± 1 2 4 3740 ± 2850 5400 ± 5 9 0 
17. Mpa'R,R-MeTec2 Sar7AVT 4700 ±745 9564 ± 3 4 1 2 55100 ± 6 2 0 0 
18. Mpa'D-Trp2 Sar7AVTa 37.6 ± 2 3 . 2 888 ± 2 1 0 4960 ± 5 1 0 
19. Mpa'S-Tic2 Sar7AVTc * * * 
a Kj values of the labelled OT antagonists were measured by Imre Pâvô 
b determination of the absolute configuration has not been done 
* the parameters were not measured 
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Table 1 summarizes the Kj values of the tested OT analogues to the OT, VPi and VP2 receptors. 
In the first part of the Table contains the Kj values of the differently substituted phenylalanine 
derivatives. 
1. Peptides containing Dmf at position 2 resulted in compound with a high affinity. It 
was similar to that of atosiban. This peptide has lower affinity to the different types of 
VP receptors. Incorporation further methyl group at position 6 of the phenylalanine 
ring (Tmf) decreased the affinity to both receptors. 
2. In case of the halogenizated phenylalnine derivatives, the Cpa (phenyalainine ring is 
substituted with chloride at position 4) has a highest affinity to the OTR, but it has 
also similar affinity to the VPRs; it can not differentiate these receptors. 
3. The peptides incorporated pentafluoro phenylalanine derivatives (L, and D-Pff) have 
lower affinity to the OTR than the previously mentioned. As concern Pff, the 
incorporation of the L and D configuration of the amino acid resulted in analogues 
with different affinity. Building of the D configuration resulted in higher affinity and 
selectivity to the OTR. 
4. The compound containing Dbr at position 2 (phenylalanine ring is substituted with a 
hydroxyl group and two bromide) has a weak affinity to the OTR, and VPj receptor, 
but it has one order of magnitude higher affinity to the VP2 receptor. 
The second part of the Table 1 contains the K; values of the peptides containing different rigid 
structure at position 2. 
1. Substitution at position 2 with the L and D configuration of the Igl resulted in the 
compound with the highest affinity. They have two orders of magnitude lower affinity 
to the VPRs, but they can not identify the two types of VPR. 
2. Substitution of the aminotetralin-2-carboxylic acid with a methoxy group (MeOAtc) 
resulted in analogue with two order of magnitude higher affinity to the OTR than the 
mother compound (Ate). This modification of the molecule did not prove the affinity 
to the VPRs. 
3. The uterotonic receptor affinity of the OT analogue incorporated Trp derivatives (D-
Trp) was found to be higher than the affinity to the two types of VPRs. It can also 
differentiate the VPRs, it has higher affinity to the VP2 receptors than VPi receptor. 
4. The modification of the Trp analogue led us to introduce Car, which is a constrained 
analogue of Trp. The I-Car, II-Car displayed practically no binding to the uterotonic 
receptor, and the VP2 receptor affinity was negligible in both cases. The VPi affinities 
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were relatively low in both cases. Thus, with a 3 order of magnitude decrease in the 
OT and VP2 binding, these analogues are selective VPi receptor agonists. 
The selectivity is one the most important parameters of a molecule, because it determines the 
side effect profile of a molecule. The selectivity ratio is a parameter, which can characterize a 
compound. The selectivity ratio was calculated from the Kj values for the OTR and the 
different types of VPRs. The lower selectivity ratio of a compound represents the better 
selectivity to the OTR. The Table 2 gives the selectivity ratios of the newly synthesized OT 
antagonists. 
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Table 2. 
Selectivity ratios of the tested peptides 
Tested peptides Selectivity ratio 
OT/VPj OT/VP2 
atosiban 0,004 0,008 
1. Mpa'l-Dmf2 Sar7AVTb 0,031 0,021 
2. Mpa'l-Tmf2 Sar7AVTb 0,183 0,121 
I. 3. Mpa'D-Cpa2 Sar7AVTa 1,125 3,214 
4. Mpa'D-Pff2 Sar7AVT 0,010 0,023 
5. Mpa'L-Pff2 Sar7AVT 0,067 0,023 
6. Mpa'L-Dbt2 Sar?AVTa 1,222 21,71 
7. Mpa'D-Igl2 Sar7AVT 0,014 0,009 
8. Mpa'L-Igl2 Sar7AVT 0,034 0,042 
9. Mpa'S-Ate2 Sar7AVTa 0,021 0,161 
10. Mpa'R-Ate2 Sar7AVTa 0,726 0,359 
11. Mpa'MeOAte2 Sar7AVT 0,029 0,034 
12. Mpa'D-Trp2 Sar7AVTa 0,042 0,008 
II. 13. Mpa'l-Car2 Sar7AVTa,b 134,6 
14. Mpa'll-Car2 Sar7AVTa'b 3227 
15. Mpa'S-Tee2 Sar7AVT 0,944 0,846 
16. Mpa'R-Tcc2 Sar7AVT 0,404 0,112 
17. Mpa'SjS-MeTee2 Sar7AVT 0,540 0,374 
18. Mpa'R,R-MeTec2 Sar7AVT 0,491 0,085 
a Kj values of the labelled OT antagonists were measured by Imre Pâvô 
b determination of the absolute configuration has not been done 
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None of the tested analogues had such a high selectivity as atosiban. 
1. Six of the synthesised exhibited relatively good selectivities: Mpa'D-Trp2Sar7AVT, 
Mpa1 D-Pff2 Sar7 A VT, Mpa'D-IgPSa^AVT, Mpa1MeoAtc2Sar7AVT, 
Mpa1 Dmf2Sar7AVT, Mpa'L-Pf^Sa^AVT. It means that these compounds two orders 
of magnitude higher affinity to the OTR than the VPRs. 
2. The constrained derivatives of Trp, peptides containing Car at position 2 proved to be 
selective to the VPRs, extremely to the VP2 receptor. 
VII/2. Results of the in vitro uterine contractility studies 
In vitro contractility studies were performed with 8 OT analogues to characterize the 
biological activity of these peptides. An initial series of studies was undertaken to determine 
the effects of the tested peptides on OT-induced contraction in isolated strips of pregnant 
guinea-pig uterus. OT induced dose-related increases in basal tone, amplitude and frequency 
of contraction with maximum effects. In the presence of the newly synthesised OT 
antagonists, the maximum effects caused by OT were significantly decreased F(9,72)=5.276, 
p=0.0001 (Figures 8 and 9). 
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Figure 8. 
The dose-response curves represent the effects of OT on isolated guinea-pig uterus alone and in the presence of 
the newly synthesized OT antagonists. The spontaneous uterine contractility was taken as 100%. All of the tested 
peptides significantly decreased the maximum effect observed with OT, without any significant change in the 
ED5O value. (Values are given as means +S.E.M.) 
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Figure 9. 
Statistical comparison of the antioxytocic effects of the tested peptides. Each bar represents the maximum effects 
of OT alone and in the presence of the tested peptides in the isolated pregnant guinea-pig uterus (results of 
Newman-Keuls post hoc test, ns: not significant, *: p<0.05; **: p<0.01; ***: p< 0.001) 
In contrast, in the presence of atosiban, a higher concentration of OT was required to elicit the 
same, degree of myometrial contractility. In isolated guinea-pig uterine strips, atosiban (108 
M) displaced the OT dose-response curve to the right in a parallel fashion, without significant 
change in the maximum effect (Figure 10). 
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Figure 10. 
The dose-response curves represent the effect of OT alone and in the presence of atosiban. The spontaneous 
uterine contractility was taken as 100%. Atosiban did not decrease the maximum effect of OT, but significantly 
changed the EDS0 of OT. (Values are given as means +S.E.M.) 
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VII/3. Results of the in vivo uterine contractility 
The aim of the next series of experiments was to examine the ability of twelve newly 
synthesized OT antagonists to inhibit the spontaneous contractility in the 24-hour postpartum 
rat uterus. Four compounds were selected on the basis of their good in vitro effectivities. The 
OT antagonists were administered intravenously, in a cumulative manner (the first dose was 
0.001 mg/kg). All the tested peptides markedly suppressed the myometrial contraction in a 
dose-dependent way (Figure 11). 
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Figure II. 
The dose-response curves represent the inhibitory effects of the tested peptides on the postpartum rat in vivo. 
The tested peptides were given intravenously, in a cumulative way. (The data are the averages of the results of 
six independent experiments; values are given as means ±S.E.M.) 
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The calculated maximum inhibition of the spontaneous uterine motility and ED5o values are 
listed in Table 3. 
Table 3. 
Calculated maximum inhibition and E D 5 Q values of the tested peptides 
Tested peptides Maximal effect (%) EDS0 (pg/kg) 
Fenoterol 93,45 1,001 
Atosiban 50,23 5,568 
1. Mpa lDmf2Sar7AVT 45,57 5,33 
2. Mpa'D-Cpa2Sar7AVT 43,34 4,41 
I. 3. Mpa lTmf2Sar7AVT 36,18 6,449 
4. Mpa'D-Pff2Sar7AVT 35,22 8,29 
5. Mpa'L-Dbr2 Sar7AVT 29,62 7,23 
6. Mpa'D-Trp2 Sar7AVT 71,17 2,72 
7. Mpa'S-Tic2 Sar7AVT 66,76 2,61 
8. Mpa'll-Car2 Sar7AVT 54,05 4,23 
II. 9. Mpa'R-Atc2Sar7AVT 39,99 2,24 
10. Mpa'D-Igl2Sar7AVT 38,04 6,28 
11. Mpa'S-Ate2 Sar7AVT 37,39 1,34 
12. Mpa'l-Car2 Sar7AVT 27,44 5,13 
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These data demonstrate that all of the tested peptides are effective in inhibiting the 
spontaneous contractility of the rat uterus in vivo. For comparison, in the same system we 
tested ^-adrenergic agonist fenoterol. Fenoterol exerts a substantially more pronounced 
inhibitory effect on postpartum rat uterus. 
Part I. of Table 3. contain the differently substituted phenylalanine derivatives. 
1. Peptides containing Dmf at position 2 proved to be the more potent compound. The 
antioxytocic activities of these peptides comparable with atosiban. Incorporation of 
further methyl group to the phenylalanine ring, Tmf decreased the inhibitory effect. 
2. Incorporation Cpa (phenylalanine ring is substituted one chloride) resulted in an 
analogue with similar potency to Dmf. 
3. Further halogenization of the phenyalanine ring decreased the potency of the 
compounds (D-Pff, L-Dbr) with lower potency. 
The part II. of Table 3. contains the peptides incorporated rigid structure of the amino acids. 
1. Substituted with D-Trp and S-Tic at position 2 proved to be more potent than 
atosiban, although the differences were not significant statistically. 
2. The two configuration of the constrained Trp analogue (I-Car, II-Car) resulted in 
different potency compounds. Incorporation of one enatiomer of Car did not lead to 
significantly effective compound. Peptide containing II-Car has similar effectivity 
than the atosiban. 
3. The other rigid phenyalanine derivatives (D-Igl, R-Atc, S-Atc) resulted in analogs 
with similarly moderate activity. Incorporation of the two configuration of Ate 
resulted in analogues with similar effectivity. 
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VIII. DISCUSSION 
Preterm labor is one of the major causes (75% to 80%) of perinatal morbidity and mortality. 
The social and economic consequences of the preterm birth in term of mental anguish and 
cost of caring for preterm infants and the associated lifelong infirmities are enormous. 
Currently it is probably the most important problem to be addressed by modem obstetric 
research. At present, tocolytic treatment is not prophylactic but commences after the onset of 
labor. The first line of treatment of preterm labor is the use of p-adrenergic agonists, but these 
agents are not ideal therapy for preterm labor. In fact, their use is associated with a high 
failure rate and a significant side effect liability. The most common side effects are associated 
with p-agonist actions on the maternal cardiovascular system and metabolism. Therefore, the 
development of specific new tocolytic agents without the side effect liability of the P-
adrenergic agonists has an important clinical justification. 
Although the role of OT in the spontaneous onset of labor remains controversial, it may be 
concluded that OT antagonists offer potentially useful approach for the management or even 
the prevention of uncomplicated preterm labor. This primary attraction is their apparent 
myometrial selectivity and the lack of side-effects as compared with other available therapies, 
e.g. P-mimetics. A number of studies have dealt with the design and pharmacological 
investigation of new OT antagonists. During the development of the OT antagonists, 
modification of the amino acids in the OT molecule at positions 1, 2, 4 or 7 and 8 produced 
analogues with higher receptor affinities for the myometrium in vitro [Gronka, Z., 1991; 
Gronzak, Z., 1983; Lebl, M.; 1987; Melin, P., 1986; Pávó, I., 1994]. The most potent of these 
was atosiban, which subsequently underwent clinical evaluation. Long-term exposure to 
atosiban in vitro does not affect myometrial sensitivity to OT, therefore it is unlikely that the 
in vivo administration has any residual effect on uterine sensitivity to OT. Moreover, 
atosiban does not affect the response of the cells to prostaglandins, suggesting that the cells 
remain responsive to other G protein-coupled receptors [Phaneuf, S., 1994]. 
In this study, the synthesised peptides are l-deamino-7-sarcosine-8-arginine analogues. The 
position 2 plays a crucial role in determining the antagonistic property. Therefore, Tyr at 
position 2 was modificated in these compounds. 
The nature peptides have an extensive conformational freedom. This is the reason that the 
same peptide chain can cause different biologic effect. These small, flexible molecules and 
their three-dimensional structure depend highly on the environment in solution. Modulation of 
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the flexibility of a peptide backbone from an extended conformation to a P-turn structure is an 
important breakthrough in the rational design of highly selective and active peptide. We 
attempted to restrict this relatively extensive conformational freedom in order to stabilize the 
bioactive antioxytocic conformation. There are different possibilities for the insertion of 
definite constraints into a peptide backbone: by introduction of a constrained amino acid; the 
introduction of a cyclic amino acids or side-chain cyclised amino acids; the formation of 
mono- or polycyclic structures involving disulphide bridges; cyclisation of the side-chain to 
the backbone, or cyclisation of the C-terminal to the N-terminal. 
Our approaches in the design of more effective OT antagonists are based mainly on the 
incorporation of bulky apolar side-chain amino acids with a conformationally constrained 
restricted feature at position 2 [Hruby, V.J., 1994; Manning, M., 1989,1995 a, 1995 b]. 
The rationale for the development of OT antagonists was based on producing a novel 
compound that mimicked normal physiological processes with high uterine specificity. The 
specificity for the OTR in the uterus is the key to the clinical application of the OT 
antagonists, since the major problem with all current tocolytic agents is their systemic 
activity, which causes potentially harmful multiorgan side-effects. 
The first step in this screening investigation was the determination of the affinity and the 
selectivity of the newly synthesised OT analogues to the OTR. They were carried out by 
radioligand binding assay on late-pregnant guinea-pig uterus, and rat kidney and liver 
membrane preparation in the presence of tritiated OT and VP. The results of receptor analyses 
indicate that generally those OT antagonists that contain Phe derivatives at position 2 have 
higher affinity and selectivity for the OTR than those do containing substituted Trp or Tyr 
analogues. It is conceivable that the incorporation of a substituted Trp analogue into the 
peptide results in a molecule that is too large and rigid to bind to the apolar side-chain binding 
pocket of the OTR. However, the incorporation of the D configuration of the Trp resulted in a 
high affinity and selectivity analogue. The good binding parameters of this molecule led us to 
introduce Car, which is a constrained analogue of the Trp. The compound containing Car has 
low affinity and selectivity to the OTR. It proved to be selective to the VPi receptor. Further 
modification of this amino acid, replacement of the carboxylic acid into the position 3 of the 
phenyalalanine ring (Tcc) and building a methyl group into the position 1 of the 
phenylalanine ring (MeTcc) improves the affinity and selectivity to the OTR. 
In order to achieve better affinity, different phenylalanine derivatives were synthesised for 
incorporation. Of these compounds, Dmf, Cpa, D, and L-Igl resulted in the compounds with 
the highest affinities, similar to that of atosiban, but they had no such good selectivity as 
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atosiban. In case of Dmf, incorporation of a further methyl group into position 6 of the 
phenylalanine ring (Tmf) decreased the affinity for the OTR and destroyed the selectivity, too. 
Substitution of the phenylalanine ring with halogen atoms decreased the affinity for the OTR. 
Peptide containing Cpa has a highest affinity to OTR, but it is not selective. Incorporation five 
fluoride atoms into the phenylalanine ring resulted in a compound with the highest selectivity. 
The binding to the OTR of the D isomer of this phenylalanine derivative is higher than in the 
case of the L isomer. 
The MeOAtc was designed by modification of the OT analogue containing Ate at position 2. 
The MeOAtc, has higher affinity and selectivity than those of the original molecule. The 
presence of the methoxy at position 6 of the tetraline ring improves the interaction of the 
analogue and the OTR. 
Summarizing the results of the receptor-binding experiments, the bulky, conformationally 
constrained amino acids at position 2 have a great influence on the receptor-ligand interaction. 
According to the results of these experiments, incorporation of the differently substituted 
phenylalanine derivatives and the nonsubstituted D-Trp resulted in the compounds with the 
best binding parameters. 
In vitro contractility studies were performed for the determination of the biological activity of 
these compounds. We measured the effects of the tested peptides on OT-induced contraction 
in isolated strips of pregnant guinea-pig uterus. Eight OT analogues were selected to these 
studies on the base of their binding parameters. The results of the in vitro contractility study 
indicate that all the tested peptides are non-competitive antagonists, in contrast with atosiban, 
which is a competitive one [Paneuf, S., 1994]. This pharmacological characteristic can not be 
explained by the chemical features of these peptides. Washing experiments demonstrated that 
none of the synthesised OT antagonists can produce an irreversible interaction to the binding 
sites of the OTR and VPRs. Pregnant guinea-pig uterine membrane was preincubated in the 
presence of the tested peptides for 30 min at 37 °C, and the specific binding was then 
measured as described in the Methods. The rest of the preincubated membrane fraction was 
diluted to a 15-folds volume and centrifuged, and the specific binding was measured again. 
This dilution-centrifugation-binding procedure was performed three times. There was no 
significant decrease in the number of specific binding sites. Consequently, this non-
competitive antagonism is due to the size and structure of the apolar side-chain of the amino 
acid at position 2. In the new peptides, the amino acids at this position are more 
conformationally constrained than that in atosiban, which can explain their behaviour. 
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In the in vivo studies a Millar catheter fitted with latex microballoon was inserted in the 
postpartum rat uterus. In spite of the obvious hormonal differences between the postpartum 
rat and human situation, this preparation can be regarded as an animal model of pregnancy 
[Csapo, A.I., 1982]. The in vivo experimental pharmacological animal methods the 
experiments were carried out on 24 hours postpartum rat uterus. During the in vivo 
experiments the spontaneous contraction were the strongest after 24 hours, though the values 
after 12 and 48 hours were also significantly increased as compared to the 1-hour value 
[Zupko, I., 1997] 
The results in vivo experiments support the pharmacological antagonistic characteristic of 
these peptides. All of the tested peptides inhibited the intrinsic OT-induced contraction in a 
dose-dependent manner. The incorporation of D-Trp and a rigid structure of the 
phenylalanine, Tic resulted in the most effective OT antagonists among the tested peptides. 
This may be due to the size and the arrangement of the side-chain of the amino acids at 
position 2. Modification of the Trp resulted in Car destroyed the efficacy of the molecule, but 
there was a significant differences between the two configuration of the amino acid. 
Incorporation of the II-Car (the absolute configuration has not been determined) resulted in an 
antagonist with a strong inhibitory effect. The substituted phenylalanine derivative, Dmf also 
resulted in a moderate effective compound, similar to atosiban. The phenylalanine ring 
substituted at positions 2 and 4 with methyl groups is needed for antioxytocic activity. 
Incorporation of a further methyl group into the phenylalanine ring (Tmf) decreased the 
efficacy of the peptide. The further phenylalanine derivatives have weaker effect on 
postpartum rat uterus. 
As regards these syntheses of OT antagonists, the incorporation of D-Trp, S-Tic and Dmf at 
position 2 resulted in a peptide that was nearly equipotent to atosiban. These compounds have 
similar binding parameters for the OTR and inhibitory effects in the in vivo system. However, 
the atosiban has a better selectivity for the OTR. 
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IX. FINAL CONCLUSION 
The favourable safety profile of selective OT antagonists, in combination with equivalent 
tocolytic effectiveness would appear to represent an advance over current tocolytic therapy. 
When treating preterm labor, it is essential to balance the relative risks and benefits of the 
treatment against expected maternal and foetal outcomes. Today, the decision to administer or 
continue tocolytic therapy appears to concentrate on the tolerability of current tocolytic agents 
or more importantly their poor side effect profile. 
Exact localization of the OTR was determined in the recent past. OTR can be found the all 
body, for example kidney, heart and cardiovascular system, thymus, fat cells, pancreas, 
adrenal gland and central nervous system. In a view of the widespread OT-related actions 
(sexual, maternal and social behaviour, memory and learning, tolerance and dependence to 
opiods, central disorder) OT antagonists may not only be regarded as promising candidates to 
prevent preterm labor, but may together with OT agonists also prove useful for treatment of 
psychiatric illnesses such as anxiety, drug abuse, sexual dysfunction, and eating disorders. 
In consequence of the pseudoirreversible pharmacological properties of the newly synthesised 
OT antagonists, these peptides comprise a novel group of OT antagonists for potential clinical 
use. Besides the weak side effect profile, this non-competitive pharmacological nature may be 
of therapeutic benefit because of the sustained effect on the myometrium. The advantages and 
possible disadvantages of the non-competitive OT antagonists need to be evaluated 
thoroughly in further pharmacological and clinical investigations. 
In the near future, a well-tolerated, effective, specific and rationally designed tocolytic agent 
may change the procedure of tocolysis. The non-competitive OT antagonists may be among 
such promising drug novelties. 
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